Ocugen, Inc.
OCGN evidence brief
What we can confirm
- BioSniper Score:
- 6.8 / 10
- Market Cap:
- $349.3M
- Lead Asset:
- neocart (Phase 3)
What it means
What to watch
Prepared research question
What matters most for OCGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OCGN
Ocugen, Inc. is a biotechnology company developing modifier gene therapies for inherited retinal diseases and age-related macular degeneration, with multiple programs in Phase 2/3 and Phase 3 trials and a financial runway extended to 2028 via convertible notes.
Key risk: Negative equity and net loss
BioSniper Score
Based on 4 of 6 signals
Market Cap
$349.3M
Cash Runway
—
Lead Asset
neocart (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 8 pipeline candidates · 7 clinical trials for Ocugen, Inc..
Ocugen, Inc. is a biotechnology company developing modifier gene therapies for inherited retinal diseases and age-related macular degeneration, with multiple programs in Phase 2/3 and Phase 3 trials and a financial runway extended to 2028 via convertible notes.
- Cash & equivalents of $100.1M as of 2026-06-30 [sec].
- Total revenue of $1.5M and net income of -$24.9M for the period ending 2026-06-30 [sec].
- Secured $130M through convertible notes, extending financial runway to 2028 [news · 2026-06-25].
- OCU400 (retinitis pigmentosa) is in Phase 3 with potential BLA/MAA filings by mid-2026 [news · 2025-05-09].
- OCU410ST (Stargardt disease) Phase 1 results published in January 2026, with Phase 2/3 pivotal trial initiated mid-2025 [news · 2026-01-12][news · 2025-05-09].
What works
- OCU410 for geographic atrophy showed a statistically significant 31% reduction in lesion growth versus control at 12 months (p<0.05) in Phase 2, supporting Phase 3 initiation [news · 2026-03-24].
- OCU410ST Phase 1 GARDian1 trial demonstrated favorable safety and tolerability with clinically meaningful functional and structural benefits in Stargardt disease [news · 2026-01-12].
- The company has secured $130M in convertible notes, providing a financial runway to 2028 and reducing near-term financing risk [news · 2026-06-25].
What to weigh
- The company reported a net loss of -$24.9M and negative shareholders' equity of -$16.6M as of 2026-06-30 [sec].
- OCU500, an inhaled mucosal COVID-19 vaccine, remains in Phase 1 with 294 competitors in the same space, indicating a highly crowded and uncertain market [pipeline].
- OCU410 BLA filing is not expected until 2028, meaning significant time and capital are required before potential commercialization [news · 2026-09-02].
From the filings
Quoted directly from source documents.
OCU410 Phase 2 data showed statistically significant reduction in lesion growth.
“Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)”
News · March 24, 2026
OCU410ST Phase 1 results support favorable safety and tolerability.
“Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients”
News · January 12, 2026
Ocugen secured $130M convertible notes extending runway to 2028.
“Ocugen has secured $130 million through convertible notes, extending its financial runway until 2028.”
News · June 25, 2026
OCU400 Phase 3 is on target for BLA/MAA filings by mid-2026.
“OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026”
News · May 9, 2025
Catalyst timeline
- 2022-01-24 · Phase 2 start for OCU400 (retinitis pigmentosa) — Initiated Phase 1/2 study for retinitis pigmentosa and LCA.
- 2023-02-23 · Phase 2 start for OCU410 (geographic atrophy) — Initiated Phase 1/2 study for geographic atrophy secondary to dry AMD.
- 2023-08-25 · Phase 3 start for OCU410ST (Stargardt disease) — Initiated Phase 1 study and Phase 2/3 pivotal confirmatory trial for Stargardt disease.
- 2024-01-13 · Phase 1 start for OCU200 (diabetic macular edema) — Initiated Phase 1 study for center-involved diabetic macular edema.
Risks & what to watch (3)›
Key risks
- Negative equity and net loss — Shareholders' equity of -$16.6M and net loss of -$24.9M as of 2026-06-30 indicate ongoing capital erosion [sec].
- OCU500 competitive landscape — OCU500 (COVID-19 vaccine) faces 294 competitors, many in Phase 2/3, making market entry challenging [pipeline].
- Late-stage clinical execution risk — OCU410 BLA filing not expected until 2028, requiring sustained funding and successful Phase 3 outcomes [news · 2026-09-02].
What to watch
- OCU400 Phase 3 data and potential BLA/MAA filings by mid-2026 [news · 2025-05-09].
- OCU410ST Phase 2/3 pivotal trial results and regulatory progress [news · 2025-05-09].
- OCU410 Phase 3 initiation in Q3 2026 and BLA filing expected in 2028 [news · 2026-03-24][news · 2026-09-02].
- Financial runway management as cash burn continues with net losses [sec].
Sources: Catalysts · News · Pipeline · Generated October 3, 2026 · How we verify sources →
Run Ocugen, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ocugen, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$25M
Lead: Phase 3
8 candidates
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
137
Total value held
$198.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 13,804,111 | $25.0M |
| millennium management llc | 13,727,192 | $24.8M |
| state street corp | 9,670,191 | $17.5M |
| marshall wace, llp | 8,052,350 | $14.6M |
| blackrock, inc. | 7,304,979 | $13.2M |
| ubs group ag | 7,280,320 | $13.2M |
| rtw investments, lp | 6,666,666 | $12.1M |
| geode capital management, llc | 4,227,104 | $7.7M |
| ikarian capital, llc | 3,962,972 | $7.2M |
| qube research & technologies ltd | 3,773,066 | $6.8M |
Showing top 10 of 137 institutional holders of Ocugen, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 21.0%
- Days to cover
- 7.4
- Shares short
- 67,890,507
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OCGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ocugen, Inc.?
Ocugen, Inc. is a biotechnology company developing modifier gene therapies for inherited retinal diseases and age-related macular degeneration, with multiple programs in Phase 2/3 and Phase 3 trials and a financial runway extended to 2028 via convertible notes.
What is Ocugen, Inc.'s lead drug candidate?
Ocugen, Inc.'s most advanced tracked candidate is neocart (Phase 3) for Repair of knee cartilage injuries in adults.
Who is the CEO of Ocugen, Inc.?
Dr. Shankar Musunuri M.B.A., Ph.D. is the chief executive officer of Ocugen, Inc. (OCGN).
Where is Ocugen, Inc. headquartered?
Ocugen, Inc. (OCGN) is headquartered in Malvern, PA, United States.
What therapeutic areas does Ocugen, Inc. focus on?
Ocugen, Inc. develops therapies across Gene Therapy, Ophthalmology, Infectious Disease, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.